Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Updates on frontline brentuximab vedotin for peripheral T-cell lymphoma

Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, describes the FDA approval of brentuximab vedotin in combination with chemotherapy for patients with previously untreated peripheral T-cell lymphomas (PTCL). Approval was based on results from the Phase II ECHELON-2 trial (NCT01777152) of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in CD30+ mature T-cell lymphomas. Dr Jagadeesh discusses data presented at the ASH 2020 meeting which showed continued benefit with brentuximab vedotin plus CHOP. The SGN35-032 trial (NCT04569032) will explore brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A+CHP) for patients with previously untreated PTCL with under 10% CD30 expression. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Deepa Jagadeesh, MD, PhD, has received research funding from ADC Therapeutics, AstraZeneca, Debiopharm Group, MEI Pharma, Regeneron, Rhizen Pharma, Seagen, Trillium Therapeutics and LOXO Pharma.